May 21, 2020
A number of companies launched their new products upon their NHI price listing on May 20, including Nippon Shinyaku’s sakigake -designated Duchenne muscular dystrophy (DMD) treatment Viltepso (viltolarsen). Viltepso is indicated for DMD with confirmed loss of the dystrophin gene...read more